Delivery Order SPE2DB22D3301-SPE2DB25FZ0TR
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a $28,753.09 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 13, 2025, for the supply of Ondansetron ODT 4mg tablets (30-count units). This is a non-set-aside competitive award with an ultimate completion date of October 9, 2025. The contract is fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as one of the nation's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of approximately $25.3K. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures, and scheduled for completion by September 12, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 per unit, with a ceiling value of $6,699.06. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order is a...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Ondansetron ODT 4 mg tablets in a 30-count quantity. This firm fixed-price delivery order, valued at $7,580.15, represents a competitively awarded non-set-aside contract with an ultimate completion date of August 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This competitive, non-set-aside delivery order carries a ceiling value of approximately $15.1K with firm fixed pricing and is scheduled for completion by September 15, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and leverages its established...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order on September 2, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $11,820.11 under a firm fixed-price arrangement, with an ultimate completion date of September 3, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $35,913.34 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, which aligns with the contractor's corporate headquarters location. The award represents a...
- The Defense Logistics Agency awarded a delivery order valued at $27,766.85 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on August 12, 2025, with an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $6,179.85 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This competitively awarded, non-set-aside contract carries a firm fixed price and is scheduled for completion by August 14, 2025. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0TRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 with a ceiling value of $4,186.92. This competitive, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by September 11, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999.99 million through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems worldwide. The Ondansetron ODT tablets represent routine pharmaceutical procurement for the Defense Health Agency and related military medical programs, consistent with the company's extensive portfolio of competitively awarded contracts covering branded and generic medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 9/10/25 |